Cadila inks pact to sell rights of cholesterol lowering drug in US, Canada to Medicure
Under terms of the agreement, Cadila will receive an upfront payment of $5 million and $2 million in deferred payments to be made over the next four years, contingent payments on achievement of sales milestones and royalties on net sales, it added.